New York State Common Retirement Fund Acquires 4,765 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

New York State Common Retirement Fund increased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 9.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,492 shares of the company’s stock after buying an additional 4,765 shares during the period. New York State Common Retirement Fund owned 0.06% of Intellia Therapeutics worth $1,661,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of NTLA. ARK Investment Management LLC raised its position in shares of Intellia Therapeutics by 14.7% during the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock valued at $347,966,000 after acquiring an additional 1,463,820 shares during the last quarter. Rhenman & Partners Asset Management AB lifted its stake in Intellia Therapeutics by 1,600.0% in the third quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company’s stock valued at $26,877,000 after buying an additional 800,000 shares during the period. Federated Hermes Inc. boosted its holdings in Intellia Therapeutics by 13.8% during the fourth quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company’s stock worth $61,477,000 after buying an additional 244,722 shares during the last quarter. abrdn plc acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $4,704,000. Finally, Sumitomo Mitsui Trust Holdings Inc. increased its stake in shares of Intellia Therapeutics by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,520,295 shares of the company’s stock valued at $111,312,000 after acquiring an additional 125,639 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $24.86 on Friday. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -4.60 and a beta of 1.85. Intellia Therapeutics, Inc. has a 52 week low of $19.37 and a 52 week high of $47.48. The stock’s 50 day moving average price is $25.50 and its two-hundred day moving average price is $27.20.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The business had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. On average, equities research analysts forecast that Intellia Therapeutics, Inc. will post -5.57 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In related news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now owns 81,571 shares in the company, valued at $2,691,027.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. The Goldman Sachs Group cut shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $136.00 to $32.00 in a report on Friday, February 23rd. Wolfe Research started coverage on Intellia Therapeutics in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. Canaccord Genuity Group boosted their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Friday, February 23rd. Finally, Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.